Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: onr:"swepub:oai:DiVA.org:umu-145129" > Ovarian cancer earl...

1 av 1
Föregående post
Nästa post
Till träfflistan

Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels : Results from the EPIC cohort

Fortner, Renée T. (författare): German Cancer Research Centre

Schock, Helena (författare): German Cancer Research Centre

Le Cornet, Charlotte (författare): German Cancer Research Centre

visa fler...

Hüsing, Anika (författare): German Cancer Research Centre

Vitonis, Allison F. (författare): Brigham and Women's Hospital / Harvard Medical School

Johnson, Theron S. (författare): German Cancer Research Centre,Istituto Nazionale dei Tumori

Fichorova, Raina N. (författare): Brigham and Women's Hospital / Harvard Medical School,Harvard Medical School

Fashemi, Titilayo (författare): Brigham and Women's Hospital / Harvard Medical School

Yamamoto, Hidemi S. (författare): Brigham and Women's Hospital / Harvard Medical School

Tjonneland, Anne (författare): Danish Cancer Society

Hansen, Louise (författare): Danish Cancer Society

Overvad, Kim (författare): Aarhus University

Boutron-Ruault, Marie-Christine (författare): Stabilite genetique et oncogenese,University of Paris-Saclay,Centre for Research in Epidemiology and Population Health (CESP)

Kvaskoff, Marina (författare): Stabilite genetique et oncogenese,University of Paris-Saclay,Centre for Research in Epidemiology and Population Health (CESP)

Severi, Gianluca (författare): Centre for Research in Epidemiology and Population Health (CESP),Human Genetics Foundation (HuGeF),University of Paris-Saclay,Stabilite genetique et oncogenese

Boeing, Heiner (författare): German Institute of Human Nutrition

Trichopoulou, Antonia (författare): National and Kapodistrian University of Athens,Hellenic Health Foundation, Athens

Papatesta, Eleni-Maria (författare): Hellenic Health Foundation, Athens

La Vecchia, Carlo (författare): Hellenic Health Foundation, Athens,University of Milan

Palli, Domenico (författare): Cancer Research and Prevention Institute (ISPO)

Sieri, Sabina (författare)

Tumino, Rosario (författare): Civic and M.P Arezzo Hospital

Sacerdote, Carlotta (författare): Citta' della Salute e della Scienza Hospital-University of Turin

Mattiello, Amalia (författare): University of Naples Federico II

Onland-Moret, N. Charlotte (författare): University Medical Center Utrecht

Peeters, Petra H. (författare): University Medical Center Utrecht,Imperial College London

Bueno-de-Mesquita, H. B(as) (författare): National Institute for Public Health and the Environment (RIVM),Imperial College London

Weiderpass, Elisabete (författare): Karolinska Institutet,UiT The Arctic University of Norway, Tromsø,Cancer Registry of Norway, Institute of Population-Based Cancer Research,Folkhälsan Research Center

Quirós, J. Ramón (författare): Public Health Directorate

Duell, Eric J. (författare): Catalan Institute of Oncology

Sánchez, Maria-Jose (författare): University of Granada,CIBER Epidemiology and Public Health (CIBERESP)

Navarro, Carmen (författare): Murcia Regional Health Council,CIBER Epidemiology and Public Health (CIBERESP)

Ardanaz, Eva (författare): Health Research Institute of Navarra (IDISNA),CIBER Epidemiology and Public Health (CIBERESP)

Larrañaga, Nerea (författare): Public Health Division of Gipuzkoa,CIBER Epidemiology and Public Health (CIBERESP)

Nodin, Björn (författare): Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine

Jirström, Karin (författare): Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine

Idahl, Annika (författare): Umeå University,Umeå universitet,Obstetrik och gynekologi,Näringsforskning

Lundin, Eva (författare): Umeå University,Umeå universitet,Patologi

Khaw, Kay-Tee (författare): University of Cambridge

Travis, Ruth C. (författare): University of Oxford

Gunter, Marc (författare): International Agency for Research on Cancer, World Health Organization

Johansson, Mattias (författare): International Agency for Research on Cancer, World Health Organization

Dossus, Laure (författare): International Agency for Research on Cancer, World Health Organization

Merritt, Melissa A. (författare): Imperial College London

Riboli, Elio (författare): Imperial College London

Terry, Kathryn L. (författare): Harvard Medical School,Brigham and Women's Hospital / Harvard Medical School

Cramer, Daniel W. (författare): Harvard Medical School,Brigham and Women's Hospital / Harvard Medical School

Kaaks, Rudolf (författare): German Cancer Research Centre

visa färre...

(creator_code:org_t)

2017-12-11
2018
Engelska.
Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 142:7, s. 1355-1360

Relaterad länk:: https://onlinelibrar...; visa fler...; http://dx.doi.org/10...; https://urn.kb.se/re...; https://doi.org/10.1...; https://lup.lub.lu.s...; http://kipublication...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; p(het)=0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection. What's new? Although CA125, a mucin produced in epithelial cells, is a known marker for ovarian cancer, complementary biomarkers are necessary for reliable early cancer detection. Here, the authors examined autoantibodies against CA125 as potential pre-diagnosis markers. Although anti-CA125 levels did not discriminate between ovarian cases and controls, discrimination of CA125 differed by levels of its antibody, with the highest discrimination among women with the highest antibody levels. The authors propose that CA125 and anti-CA125 may act synergistically for ovarian cancer early detection.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

ovarian cancer
early detection markers
CA125
anti-CA125 antibodies
MUC16
autoantibodies
anti-CA125 antibodies
autoantibodies
CA125
early detection markers
MUC16
ovarian cancer

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

International Journal of Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Fortner, Renée T ...; Schock, Helena; Le Cornet, Charl ...; Hüsing, Anika; Vitonis, Allison ...; Johnson, Theron ...; visa fler...; Fichorova, Raina ...; Fashemi, Titilay ...; Yamamoto, Hidemi ...; Tjonneland, Anne; Hansen, Louise; Overvad, Kim; Boutron-Ruault, ...; Kvaskoff, Marina; Severi, Gianluca; Boeing, Heiner; Trichopoulou, An ...; Papatesta, Eleni ...; La Vecchia, Carl ...; Palli, Domenico; Sieri, Sabina; Tumino, Rosario; Sacerdote, Carlo ...; Mattiello, Amali ...; Onland-Moret, N. ...; Peeters, Petra H ...; Bueno-de-Mesquit ...; Weiderpass, Elis ...; Quirós, J. Ramón; Duell, Eric J.; Sánchez, Maria-J ...; Navarro, Carmen; Ardanaz, Eva; Larrañaga, Nerea; Nodin, Björn; Jirström, Karin; Idahl, Annika; Lundin, Eva; Khaw, Kay-Tee; Travis, Ruth C.; Gunter, Marc; Johansson, Matti ...; Dossus, Laure; Merritt, Melissa ...; Riboli, Elio; Terry, Kathryn L ...; Cramer, Daniel W ...; Kaaks, Rudolf; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: International Jo ...

Av lärosätet: Umeå universitet; Lunds universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se